David Stokoe
Papers
1
Total Citations
114
H-Index
1
About
David Stokoe is a leading cancer biologist whose research focuses on cellular signaling pathways, particularly the KEAP1/Nrf2 pathway and its role in oxidative stress response and tumorigenesis. His major contributions include identifying mechanisms of Nrf2 activation in non-small cell lung cancer and discovering small molecule inhibitors that target this pathway. In his highly cited 2015 study (114 citations), Stokoe employed innovative mass spectrometry profiling to establish brusatol as a global protein synthesis inhibitor, demonstrating a novel approach to targeting cancers with constitutive Nrf2 activation. His work has profound implications for developing therapies against treatment-resistant tumors, bridging fundamental cell biology with translational cancer research. Stokoe’s research has been instrumental in understanding how mutations in the KEAP1/Nrf2 axis drive cancer progression and identifying vulnerabilities that can be exploited therapeutically. His findings continue to influence drug discovery efforts aimed at restoring oxidative stress sensitivity in aggressive cancers, making him a pivotal figure in the field of cancer signaling and targeted therapy development.
Research Focus
Key Achievements
Top Papers
- 1